DNM2 and breast cancer: BC-PDMs had increased protein levels of the cytoskeletal protein cytokeratin 5 and 6 (CK5/6), while expression of immune cell markers CD11c, CD16, CD68, CD8 alpha, CD25, PD1 and PD-L1 were decreased.